Top ▲
Target has curated data in GtoImmuPdb
Target id: 1628
Nomenclature: MMP1
Family: M10: Matrix metallopeptidase
This target is also described as a ligand entry: matrix metalloproteinase 1
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 469 | 11q22.2 | MMP1 | matrix metallopeptidase 1 | |
Mouse | - | 464 | 9 A1 | Mmp1a | matrix metallopeptidase 1a (interstitial collagenase) | |
Rat | - | 464 | 8q11 | Mmp1 | matrix metallopeptidase 1 |
Previous and Unofficial Names |
Collagenase-1 | fibroblast collagenase | matrix metallopeptidase 1a | Mcol-A | CLG | matrix metallopeptidase 1 (interstitial collagenase) |
Database Links | |
Specialist databases | |
MEROPS | M10.001 (Hs) |
Other databases | |
Alphafold | P03956 (Hs), Q9EPL5 (Mm), P81563 (Rn) |
BRENDA | 3.4.24.7 |
CATH/Gene3D | 2.110.10.10, 3.40.390.10 |
ChEMBL Target | CHEMBL332 (Hs) |
DrugBank Target | P03956 (Hs) |
Ensembl Gene | ENSG00000196611 (Hs), ENSMUSG00000043089 (Mm), ENSRNOG00000032353 (Rn) |
Entrez Gene | 4312 (Hs), 83995 (Mm), 300339 (Rn) |
Human Protein Atlas | ENSG00000196611 (Hs) |
KEGG Enzyme | 3.4.24.7 |
KEGG Gene | hsa:4312 (Hs), mmu:83995 (Mm), rno:300339 (Rn) |
OMIM | 120353 (Hs) |
Orphanet | ORPHA306110 (Hs) |
Pharos | P03956 (Hs) |
RefSeq Nucleotide | NM_002421 (Hs), NM_032006 (Mm), NM_001134530 (Rn) |
RefSeq Protein | NP_002412 (Hs), NP_114395 (Mm), NP_001128002 (Rn) |
SynPHARM | 82905 (in complex with CGS-27023A) |
UniProtKB | P03956 (Hs), Q9EPL5 (Mm), P81563 (Rn) |
Wikipedia | MMP1 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
Overexpression of MMP-1 degrades extracellular matrix causing damage to the colon mucosa in patients with ulcerative colitis. The MMP-1 promotes secretion of TNFα causing futher damage. Levels of MMP-1 and TNFα correlate with disease severity [10]. |
Immuno Process Associations | ||
|
||
|
||
|
Immuno Disease Associations | ||||||||||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||||||||
|
1. Castelhano AL, Billedeau R, Dewdney N, Donnelly S, Horne S, Kurz LJ, Liak T, Martin R, Uppington R, Zhengyu Yuan et al.. (1995) Novel indolactam-based inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett, 5: 1415-1420. DOI: 10.1016/0960-894X(95)00233-J
2. Close DR. (2001) Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis, 60 Suppl 3: iii62-7. [PMID:11890658]
3. Fray MJ, Dickinson RP, Huggins JP, Occleston NL. (2003) A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem, 46 (16): 3514-25. [PMID:12877590]
4. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P. (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford), 42 (1): 83-8. [PMID:12509618]
5. Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, Cummons T, Xu J, Jin G, Barone D et al.. (2006) Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett, 16 (6): 1605-9. [PMID:16426848]
6. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett, 14 (1): 47-50. [PMID:14684295]
7. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]
8. Rasmussen HS, McCann PP. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther, 75 (1): 69-75. [PMID:9364582]
9. Takeuchi T, Hayashi M, Tamita T, Nomura Y, Kojima N, Mitani A, Takeda T, Hitaka K, Kato Y, Kamitani M et al.. (2022) Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem, 65 (12): 8493-8510. [PMID:35687819]
10. Wang YD, Mao JW. (2007) Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis. World J Gastroenterol, 13 (44): 5926-32. [PMID:17990358]
M10: Matrix metallopeptidase: MMP1. Last modified on 12/07/2022. Accessed on 03/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1628.